Keyphrases
Anti-PD-1
12%
Anti-RNA Polymerase III Antibodies
6%
Antibody Detection
48%
Antisynthetase Syndrome
6%
Autoantibodies
32%
Bayesian Forecasting
8%
Checkpoint Inhibitors
48%
Clinical Performance
6%
Clinical Practice
48%
Commercial Kits
48%
Composite Score
48%
Corticosteroids
48%
Dermatomyositis
14%
Diagnostic Performance
6%
Diagnostic Research
6%
Diagnostic Tool
6%
Differential Diagnosis
48%
Euroline
48%
Group 12
6%
HMG-CoA Reductase
13%
Idiopathic Inflammatory Myopathies
48%
Idiopathic Inflammatory Myositis
41%
Immunoblot
48%
Immunoblot Assay
9%
Individual Control
6%
Induced Liver Injury
48%
Infliximab Trough Concentration
8%
Jo-1
6%
Liver Biopsy
48%
Malignancy
12%
Melanoma Differentiation-associated Gene 5 (MDA5)
20%
Method Validation
9%
Mi-2
6%
Multi-analyte
20%
Myositis-specific Antibodies
52%
Narrative Review
48%
Necroinflammation
24%
NXP2
6%
Odds Ratio
6%
Overall Sensitivity
6%
Particle-based
20%
PL-12
13%
Proactive Therapeutic Drug Monitoring
48%
Research Use
6%
Ribonucleoprotein
12%
Sensitivity Specificity
6%
Stratification Tools
6%
Systemic Sclerosis
48%
TIF1
20%
Transaminases
12%
Medicine and Dentistry
Adverse Drug Reaction
6%
Adverse Event
6%
Antibodies
48%
Crohn's Disease
6%
Diagnosis
7%
Differential Diagnosis
48%
Infection
6%
Inflammatory Bowel Disease
48%
Infliximab
48%
Infusion Related Reaction
6%
Myopathy
48%
Myositis
48%
Patient with Inflammatory Bowel Disease
12%
Pediatrics
48%
Pediatrics Patient
12%
Spontaneous Remission
6%
Therapeutic Drug Monitoring
48%
Ulcerative Colitis
6%
Immunology and Microbiology
Alternative RNA Splicing
6%
Antibodies
54%
Autoantibodies
42%
Cancer Screening
6%
Centromere
6%
Connective Tissue
6%
Dermatomyositis
24%
ELISA
6%
Immunology
100%
Immunoprecipitation
6%
MDA5
11%
Myositis
54%
Prevalence
12%
Ribonucleoprotein Antibody
6%
RNA Polymerase
6%
Systemic Scleroderma
48%
Western Blot
48%
